Improving Troponin Testing for Myocardial Infarction
New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.
New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.
The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.
In this review of April 2024, the editorial team highlighted some of the biggest stories in the pulmonary health space, touching on topics such as…
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
The deep impact of mild plaque psoriasis
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.
Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.
In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.
This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.